Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma

Oncogene

Volumn 33, Issue 17, 2014, Pages 2191-2203

  Teshima, K ^a   Nara, M ^a   Watanabe, A ^a   Ito, M ^a   Ikeda, S ^a   Hatano, Y ^b   Oshima, K ^c   Seto, M ^d   Sawada, K ^a   Tagawa, H ^a  

^a AKITA UNIVERSITY   (Japan)

^b Yamamoto Kumiai General Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

apoptosis; BMI1; mantle cell lymphoma; miR 16; Noxa; side population

Indexed keywords

BMI1 PROTEIN; BORTEZOMIB; DEXAMETHASONE; ETOPOSIDE; MICRORNA 16; PUROMYCIN; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BCL2L11 GENE; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PMAIP1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE POPULATION CELL; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, MANTLE-CELL; MEMBRANE PROTEINS; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA INTERFERENCE; SIDE-POPULATION CELLS; UP-REGULATION;

EID: 84899656046     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.177     Document Type: Article

References (58)

1. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149-165.
2. Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. Mantle cell lymphoma. In: Swerdloe AH, Campo E, Harris NL, Jaffe ES, Stein H, Thiele J, Vardiman JW eds.) World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Washington Lyon, 2008 158-178.
3. Beà S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001; 61: 2409-2412.
4. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. Genome-wide arraybased CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348-1358.
5. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271-280.
6. Beà S, Salaverria I, Armengol L, Pinyol M, Fernández V, Hartmann EM et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-3069.
7. van Lohuizen M, Frasch M, Wientjens E, Berns A. Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature 1991; 353: 353-355.
8. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428: 337-341.
9. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009; 28: 3022-3032.
10. Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G et al. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One 2011; 6: e14648.
11. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H et al. Reduced miR-128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011; 17: 7105-7015.
12. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
13. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
14. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialmesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119: 3626-3636.
15. Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P et al. The polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res 2010; 70: 5528-5538.
16. Kimura M, Takenobu H, Akita N, Nakazawa A, Ochiai H, Shimozato O et al. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells. Cancer Sci 2011; 102: 983-990.
17. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-260.
18. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003; 425: 962-967.
19. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
20. Dovey JS, Zacharek SJ, Kim CF, Lees JA. Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci USA 2008; 105: 11857-11862.
21. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008; 68: 7742-7749.
22. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34CD38- progenitor cells from patients with acute myeloid leukemia. Blood 2001; 97: 3882-3889.
23. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
24. Goodell MA, Kinney-Freeman S, Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol 2005; 290: 343-352.
25. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 and ABCG2 cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
26. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-513.
27. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159.
28. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
29. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V et al. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007; 148: 1797-1803.
30. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007; 67: 3716-3724.
31. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007; 67: 8216-8222.
32. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
33. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261.
34. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008; 68: 9125-9130.
35. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 2009; 69: 9090-9095.
36. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
37. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011; 10: 99.
38. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31: 432-445.
39. Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnaksu R, Hosokawa H et al. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med 2008; 205: 1109-1120.
40. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
41. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
42. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21: 525-530.
43. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Biom M, Zevenhoven J et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007; 12: 328-341.
44. Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, van Doorninck J et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 2008; 68: 6507-6515.
45. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 2005; 19: 2013-2016.
46. Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112: 822-829.
47. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630-2639.
48. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17- 92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009; 113: 396-402.
49. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
50. Ofir M, Hacohen D, Ginsberg D. miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 2011; 9: 440-447.
51. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang THM, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 2012; 14: R77.
52. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012; 72: 5945-5955.
53. Kim KT, Carroll AP, Mashkani B, Cairns MJ, Small D, Scott RJ. MicroRNA-16 is downregulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and Interacts with Pim-1. PLoS One 2012; 7: e44546.
54. Zhou R, Li X, Hu G, Gong AY, Drescher KM, Chen XM. MiR-16 targets transcriptional corepressor SMRT and modulates NF-kappaB-regulated transactivation of interleukin-8 gene. PLoS One 2012; 7: e30772.
55. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mRNA stability factor HuR inhibits MicroRNA-16 targeting of COX-2. Mol Cancer Res 2012; 10: 167-180.
56. Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009; 28: 2090-2099.
57. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H et al. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010; 70: 7176-7186.
58. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/ gamma(c)(null)mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182.